Vyome (HIND) Q3 2026 earnings summary

Executive summary

• Clinical-stage pipeline remains the main focus; legacy pharmaceutical products and Sun Pharma licensing generated the reported revenue.

• Q3 net loss narrowed sharply YoY as the prior-year quarter included $7.706m in transactional fees; cash at quarter-end was $6.957m.

Financial highlights

• Q3 2026 revenue was $57,998 vs $34,627 YoY; gross profit was $26,802 vs $18,050.

• 9M 2026 revenue was $116,544 vs $283,163; gross profit was $55,105 vs $196,705.

• 9M operating loss was $3.014m vs $9.097m; net loss was $2.636m vs $9.198m, with 2025 operating expenses including $7.706m of transactional fees.

• Q3 net loss was $930,325 vs $8.595m; 2026 other income included interest earned on cash and a $30,283 liability write-off gain.

Outlook and guidance

• Management expects available cash to fund operating expenses and capex for at least 15 months, including initiation of VT-1953's pivotal trial, but not trial completion or other indications.

• R&D costs are expected to increase as clinical trials and product development advance; the timing and cost of development remain uncertain.

• General and administrative expenses are expected to rise with expanded R&D, public-company compliance, and potential commercialization activities.